drugset / Trial / NCT05577845

5-HT3 Receptor Antagonist (Ramosetron) vs Loperamide for the Treatment of Low Anterior Resection Syndrome(RALARS)

NCT05577845

Recruiting 212 enrolled Seoul National University Hospital
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Safety \& Efficacy of 5-HT3 Receptor Antagonist (Ramosetron) versus Loperamide for the Treatment of Low Anterior Resection Syndrome (RALLARS): Multicenter Randomized Controlled Trial

Timeline

Start
2023-03-27
Primary completion
2025-12
Completion
2032-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Ramosetron Small molecule

Indications

No indication recorded.